Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study.

Adult Antipsychotic Agents / therapeutic use Cross-Sectional Studies Female Glutamic Acid / metabolism Humans Magnetic Resonance Imaging / methods Male Middle Aged Proton Magnetic Resonance Spectroscopy / methods Schizophrenia / diagnostic imaging Severity of Illness Index

Journal

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907

Informations de publication

Date de publication:
03 2020
Historique:
received: 07 08 2019
accepted: 07 12 2019
revised: 08 11 2019
pubmed: 17 12 2019
medline: 29 12 2020
entrez: 17 12 2019
Statut: ppublish

Résumé

Approximately 30% of patients with schizophrenia do not respond to antipsychotics and are thus considered to have treatment-resistant schizophrenia (TRS). To date, only four studies have examined glutamatergic neurometabolite levels using proton magnetic resonance spectroscopy (

Identifiants

DOI: 10.1038/s41386-019-0589-z PMID: 31842203 PMC: PMC7021829
pubmed: 31842203
doi: 10.1038/s41386-019-0589-z
pii: 10.1038/s41386-019-0589-z
pmc: PMC7021829
doi:

Substances chimiques

Antipsychotic Agents 0
Glutamic Acid 3KX376GY7L

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

632-640

Références

Magn Reson Med. 2004 Mar;51(3):435-40
pubmed: 15004781
Schizophr Bull. 2016 Mar;42(2):415-24
pubmed: 26320195
Int Psychogeriatr. 2014 Aug;26(8):1387-97
pubmed: 24832196
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2569-74
pubmed: 9122236
Schizophr Res. 2011 Dec;133(1-3):54-62
pubmed: 22000940
NMR Biomed. 2001 Jun;14(4):260-4
pubmed: 11410943
Transl Psychiatry. 2018 Jan 31;8(1):30
pubmed: 29382821
Neuropsychopharmacology. 1995 Aug;13(1):9-19
pubmed: 8526975
Neuropsychopharmacology. 2011 Aug;36(9):1781-91
pubmed: 21508933
Lancet. 1995 Oct 28;346(8983):1130-1
pubmed: 7475604
JAMA Psychiatry. 2013 Oct;70(10):1057-66
pubmed: 23966023
Psychol Med. 2020 Oct;50(13):2182-2193
pubmed: 31524118
Mol Psychiatry. 2018 Nov;23(11):2145-2155
pubmed: 29880882
Int J Neuropsychopharmacol. 2015 Jan 20;18(6):
pubmed: 25603859
Lancet Psychiatry. 2018 Oct;5(10):816-823
pubmed: 30236864
Psychiatry Res Neuroimaging. 2018 Mar 30;273:16-24
pubmed: 29414127
Neuropsychiatr Dis Treat. 2012;8:119-22
pubmed: 22536067
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
J Chem Neuroanat. 2016 Jul;74:28-46
pubmed: 26993424
J Magn Reson Imaging. 2011 Sep;34(3):645-52
pubmed: 21761460
Br J Psychiatry. 2011 Jun;198(6):448-56
pubmed: 21628707
Cereb Cortex. 1994 Jan-Feb;4(1):8-26
pubmed: 8180494
Magn Reson Med. 2016 Sep;76(3):725-32
pubmed: 26361892
Prog Neurobiol. 1995 Aug;46(5):531-40
pubmed: 8532851
Am J Psychiatry. 1999 May;156(5):675-82
pubmed: 10327898
Am J Psychiatry. 1991 Oct;148(10):1301-8
pubmed: 1654746
JAMA Psychiatry. 2019 Mar 1;76(3):314-323
pubmed: 30624573
Science. 1975 Jun 20;188(4194):1217-9
pubmed: 1145194
J Clin Exp Neuropsychol. 1998 Jun;20(3):310-9
pubmed: 9845158
Schizophr Res. 2005 Nov 15;79(2-3):231-8
pubmed: 15982856
J Psychiatry Neurosci. 2000 Mar;25(2):161-6
pubmed: 10740989
Neuropsychopharmacology. 2017 Mar;42(4):941-950
pubmed: 27857125
Am J Psychiatry. 2017 Mar 1;174(3):216-229
pubmed: 27919182
JAMA Psychiatry. 2016 Jul 1;73(7):665-74
pubmed: 27304221
Am J Psychiatry. 2007 Sep;164(9):1411-7
pubmed: 17728427
Biol Psychiatry. 2018 Mar 15;83(6):475-483
pubmed: 29132653
J Am Geriatr Soc. 1992 Dec;40(12):1221-6
pubmed: 1447438
Am J Psychiatry. 2012 Nov;169(11):1203-10
pubmed: 23034655
Biol Psychiatry. 2019 Apr 1;85(7):596-605
pubmed: 30389132
Arch Gen Psychiatry. 2012 Aug;69(8):776-86
pubmed: 22474070
Biol Psychiatry. 2014 Mar 1;75(5):e11-3
pubmed: 23890739
Arch Gen Psychiatry. 2010 Mar;67(3):231-9
pubmed: 20194823
Arch Gen Psychiatry. 1994 Mar;51(3):199-214
pubmed: 8122957
Magn Reson Med. 2017 Jan;77(1):23-33
pubmed: 26715192
Psychol Med. 2016 Nov;46(15):3231-3240
pubmed: 27605254
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7673-5
pubmed: 10884398
Psychiatry Clin Neurosci. 2006 Jun;60(3):332-9
pubmed: 16732750
Schizophr Bull. 2016 May;42(3):744-52
pubmed: 26683625
Mol Psychiatry. 2003 Jan;8(1):60-70
pubmed: 12556909
Schizophr Res. 2019 Aug;210:239-244
pubmed: 30630705
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9235-40
pubmed: 8799184

Auteurs

Ryosuke Tarumi (R)

Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.
Department of Psychiatry, Komagino Hospital, Hachioji, Japan.

Sakiko Tsugawa (S)

Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.

Yoshihiro Noda (Y)

Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.

Eric Plitman (E)

Cerebral Imaging Centre, Douglas Mental Health University Institute, McGill University, Montreal, QC, Canada.
Department of Psychiatry, McGill University, Montreal, QC, Canada.

Shiori Honda (S)

Graduate School of Media and Governance, Keio University, Tokyo, Japan.

Karin Matsushita (K)

Faculty of Environment and Information Studies, Keio University, Tokyo, Japan.

Sofia Chavez (S)

Campbell Institute Research Program, Centre for Addiction and Mental Health, Toronto, ON, Canada.

Kyosuke Sawada (K)

Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.

Masataka Wada (M)

Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.

Mie Matsui (M)

Department of Clinical Cognitive Neuroscience, Institute of Liberal Arts and Science, Kanazawa University, Kanazawa, Japan.

Shinya Fujii (S)

Faculty of Environment and Information Studies, Keio University, Tokyo, Japan.

Takahiro Miyazaki (T)

Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.

M Mallar Chakravarty (MM)

Cerebral Imaging Centre, Douglas Mental Health University Institute, McGill University, Montreal, QC, Canada.
Department of Psychiatry, McGill University, Montreal, QC, Canada.
Department of Biomedical Engineering, McGill University, Montreal, QC, Canada.

Hiroyuki Uchida (H)

Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.
Campbell Institute Research Program, Centre for Addiction and Mental Health, Toronto, ON, Canada.
ORCID: 0000-0002-0628-7036

Gary Remington (G)

Campbell Institute Research Program, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

Ariel Graff-Guerrero (A)

Campbell Institute Research Program, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

Masaru Mimura (M)

Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.

Shinichiro Nakajima (S)

Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan. shinichiro_nakajima@hotmail.com.
Campbell Institute Research Program, Centre for Addiction and Mental Health, Toronto, ON, Canada. shinichiro_nakajima@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Levels of glutamatergic neurometabolites in...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Psychoanaleptiques › Tranquillisants › Neuroleptiques › Levels of glutamatergic neurometabolites in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études transversales › Levels of glutamatergic neurometabolites in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés excitateurs › Acide glutamique › Levels of glutamatergic neurometabolites in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Levels of glutamatergic neurometabolites in...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › Levels of glutamatergic neurometabolites in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Levels of glutamatergic neurometabolites in...
questionsmedicales.fr › Techniques d'investigation › Techniques de chimie analytique › Analyse spectrale › Spectroscopie par résonance magnétique › Spectroscopie par résonance magnétique du proton › Levels of glutamatergic neurometabolites in...
questionsmedicales.fr › Troubles mentaux › Schizophrénie et troubles avec traits psychotiques › Schizophrénie › Levels of glutamatergic neurometabolites in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes de santé › Indicateurs d'état de santé › Acuité des besoins du patient › Indice de gravité de la maladie › Levels of glutamatergic neurometabolites in...